shr-1826
mAbexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Oct 30, 2023 (NCT06094556)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06935175 | Phase 2 | May 1, 2025 | Fudan University |
| NCT06915142 | Phase 2 | Apr 28, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06844474 | Phase 2 | Mar 7, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06754930 | Phase 1/Phase 2 (Phase 2) | Feb 18, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06703177 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06094556 | Phase 1 | Oct 30, 2023 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 5 | 5 | 2 | 2023 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1